TUBB Stock Overview
Operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €114.80 |
| 52 Week High | €114.80 |
| 52 Week Low | €114.80 |
| Beta | 0.44 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 80.50% |
| Change since IPO | 287.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| TUBB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 1.7% |
| 1Y | n/a | 2.2% | 8.3% |
Return vs Industry: Insufficient data to determine how TUBB performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TUBB performed against the UK Market.
Price Volatility
| TUBB volatility | |
|---|---|
| TUBB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TUBB's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine TUBB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| TUBB fundamental statistics | |
|---|---|
| Market cap | €6.38b |
| Earnings (TTM) | €90.02m |
| Revenue (TTM) | n/a |
70.9x
P/E Ratio0.0x
P/S RatioIs TUBB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUBB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.00m |
| Gross Profit | -€2.00m |
| Other Expenses | -€92.02m |
| Earnings | €90.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Aug 02, 2025
| Earnings per share (EPS) | 2.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.6% |
How did TUBB perform over the long term?
See historical performance and comparison